New melanoma drug requires gene mutation test
- Dabrafenib: First Global Approval. Ballantyne, Anita; Garnock-Jones, Karly // Drugs;2013, Vol. 73 Issue 12, p1367
Dabrafenib (TafinlarÂ®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's research programme for the discovery of selective inhibitors of mutant BRAF kinase activity, for the treatment of solid tumours; mutations in the BRAF gene are associated with increased growth and...
- Recent Advances in Melanoma Therapy. Daud, Adil // Journal of Managed Care Medicine;2014, Vol. 17 Issue 1, p33
No abstract available.
- Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities. Lemech, Charlotte; Arkenau, Hendrik-Tobias // Clinical Medicine Insights: Oncology;2012, Issue 6, p53
The last 12 months have seen the beginning of a new era in the treatment options available for patients with metastatic cutaneous melanoma, a disease previously characterised by its poor prognosis and limited treatment options. Two mechanistically diverse agents have now demonstrated an overall...
- Erratum to: Idelalisib: First Global Approval. Markham, Anthony // Drugs;Oct2014, Vol. 74 Issue 15, p1839
A correction to the article "Idelalisib: First Global Approval" by Anthony Markham, related to approval of the drug used for the treatment of relapsed chronic lymphocytic leukaemia and small lymphocytic leukaemia, that was published in a 2014 issue of the journal, is presented.
- Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. LUKE, JASON J.; HODI, F. STEPHEN // Oncologist;Jun2013, Vol. 18 Issue 6, p717
There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with...
- Cancer drug developers counteract kinase gatekeeper mutations. Mullard, Asher // Nature Reviews Drug Discovery;Oct2015, Vol. 14 Issue 10, p667
The article reports on the request of drug developers Clovis and AstraZeneca for authorization in marketing their drugs rociletinib and AZD9291 respectively in the U.S. in 2015. Topics discussed include the regulatory review of the epidermal growth factor receptor (EGFR) inhibitors for the T790M...
- First-Line NSCLC with Erlotinib: Effective, but not for Everybody. Ershler, William B. // Clinical Oncology Alert;Sep2011, Vol. 27 Issue 9, p69
The author discusses a study by C. Zhou and colleagues, which compared the efficacy of erlotinib with chemotherapy as a first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). He mentions that erlotinib led to significant improvement in quality of life of...
- Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma. Starr, Phoebe // Oncology Pharmacist;Oct2014, Vol. 7 Issue 4, p29
No abstract available.
- Ipilimumab approved for metastatic melanoma. Traynor, Kate // American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p768
The article reports that the Food and Drug Administration (FDA) approved ipilimumab, to be marketed as 'Yervoy' by Bristol-Myers Squibb, for the treatment of metastatic melanoma. It offers information on the product, an immunoglobulin G1&subk; (IgG1&subk;) monoclonal antibody, which binds to the...